Back to Trials
NCT04787471PHASE2, PHASE3Recruiting

Corneal Crosslinking for Treatment of Corneal Neovascularization

Price Vision Group

Start Date

5/3/2021

Completion Date

9/15/2026

Summary

The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * 18 years of age or older * With active inflammation or infection causing vascularization and possibly melting of the cornea, or vessels extending into the cornea causing lipid deposition, or vascularization that could significantly increase the risk of rejection of a current or planned corneal transplant, or vessels that continue to extend into the cornea despite topical treatment with corticosteroids. * Signed written informed consent. Exclusion Criteria: * Known sensitivity to treatment medications * Current condition that in the investigator's opinion could compromise safety or data integrity. * Pregnancy (including plan to become pregnant) or lactation during the course of the study

Interventions

COMBINATION_PRODUCT

30 minute photoactivation of riboflavin 0.1%

COMBINATION_PRODUCT

10 minute photoactivation of riboflavin 0.1%

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Corneal Neovascularization

Locations

Price Vision Group

Indianapolis, Indiana 46260

United States